Last updated: 2026-10-13 18:51:40. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Imunon, Inc. (IMNN) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $1.06, with a market capitalisation of $6.06M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.96 to $5.29. This page covers its latest market performance, valuation, price trends and company information.
$6.06M | |
$1.07 | |
$47.61 | |
$0.96 | |
$1.07 | |
31.49K | |
161.90K | |
-- | |
$5.29 | |
$0.96 | |
-- | |
-- |
Imunon, Inc. (IMNN) is currently trading at $1.06 as of 2026-10-13 18:46:00, down 1.40% ($0.02) from the previous close of $1.07
During today's regular trading session, IMNN has traded between $0.96 and $47.61, with a trading volume of 31.49K shares. The current price is near the lower end of today's range.
Over the past seven days, Imunon, Inc. (IMNN) moved from $1.28 to $1.06, representing a decline of 17.58% ($0.23).
The stock traded between $0.96 and $1.38 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 112.67 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 2.2%
IMNN is currently trading at $1.06, placing it 2.2% of the way from its 52-week low of $0.96 to its 52-week high of $5.29. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the coding of proteins and cytokines in the treatment of solid tumors. The second modality, PlaCCine, is developed for the coding of viral antigens that can elicit an immunological response. The company's clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 20 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Imunon, Inc. (IMNN) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.